NCT00511771No Longer Available不适用
A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Novartis
研究概览
简要总结
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 54 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •For patients with IBS-C: Women of 18-54 years of age with IBS-C according to the Rome III criteria.
- •For patients with Chronic Idiopathic Constipation: Women of 18-54 years of age with CIC according to the Rome III criteria .
- •Patients who did not have satisfactory symptom improvement of their IBS-C or CIC symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC. Satisfactory symptom improvement will be assessed by the patient.
- •Patients signed the informed consent
排除标准
- •History of or current diagnosis of cardiovascular ischemic disease (e.g., angina pectoris, myocardial infarction, transient ischemic attack or stroke and including findings suggestive of ischemia on an ECG such as changes in ST segment and T waves, and / or Q wave)
- •Patients who have uninvestigated symptoms suggestive of a cardiovascular ischaemic disease such as chest pain or chest discomfort, shortness of breath, sudden onset of weakness of the arms or the legs, difficult talking or loss of sensation etc
- •Presence of any cardiovascular risk factors according to the NIH guideline [NIH Publication No. 01-3670] (such as hypertension, hyperlipidemia, diabetes mellitus, active smoking, obesity and family history of premature coronary heart disease) as assessed by the investigator
- •Clinical evidence of significant (as judged by the Investigator) respiratory, cardiovascular, renal, hepatic-biliary, endocrine, psychiatric or neurologic diseases or presence of abdominal adhesions
- •History of or current eating disorder such as anorexia or bulimia or compulsory overeating.
- •Uncompensated depression or anxiety or suicidal ideation or behavior.
- •Diagnosis of mega-rectum or colon, a history of intestinal obstruction, congenital anorectal malformation, clinically significant rectocele, or any evidence of intestinal structural abnormality including gastrointestinal resection that affected bowel transit or any evidence of intestinal carcinoma, of inflammatory bowel disease or of alarm symptoms such as weight loss, rectal bleeding, or anemia
- •Evidence of cathartic colon or a history of drug (including laxative) or alcohol abuse, that in the Investigator's opinion, the patient is likely to continue to abuse these substances during the tIND program period
- •Pregnant women or breastfeeding women; fertile women who are not currently practicing medically approved method of contraception
- •Participating in other investigational studies concurrently or within 1 month prior to entering this tIND program
- •Hypersensitive to tegaserod or to any of the excipients
- •Patients who had tolerability or safety concerns with prior use of tegaserod.
研究者
相似试验
已完成
3 期
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of DyspepsiaDyspepsiaNCT00232037Novartis359
已完成
3 期
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of DyspepsiaDyspepsiaNCT00232102Novartis423
已完成
3 期
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.DyspepsiaNCT00171470Novartis60
已完成
4 期
Preference of Tegaserod vs. PEG 3350 in Patients With ConstipationConstipationNCT00171522Novartis52
终止
2 期
Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic GastropathyDiabetic GastropathyNCT00142974Novartis120